Clinical Trial Update: Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005) [Phase 4]

View source ↗

Summary

Phase 4 trial comparing daptomycin to standard of care in pediatric patients (1-17 years) with Staphylococcus aureus bacteremia; study completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Staphylococcus Aureus Bacteremia

Drugs mentioned

• Daptomycin (daptomycin)

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Bacteremia | Phase 4 | Status: COMPLETED | Results posted: 2016-12-07